Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.33 |
| ▸ | PDE1A | P54750 | 6/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 6/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863419 | 0.80 | NUDT1 (0.31) | PIK3CD | |
| Hydrochloric Acid SCHEMBL864070 | 0.79 | IRAK4 (0.38) | IRAK4PIK3CDPDE1APDE1BPDE1C | |
| Hydrochloric Acid SCHEMBL864071 | 0.79 | IRAK4 (0.38) | IRAK4PIK3CDPDE1APDE1BPDE1C | |
| Formic Acid SCHEMBL863792 | 0.66 | PIK3CD (0.40) | PIK3CDPDE1APDE1BPDE1C | |
| Formic Acid SCHEMBL863791 | 0.66 | PIK3CD (0.40) | PIK3CDPDE1APDE1BPDE1C | |
| Formic Acid SCHEMBL865074 | 0.65 | TNF (0.39) | PIK3CD | |
| Formic Acid SCHEMBL865075 | 0.65 | TNF (0.39) | PIK3CD | |
| Hydrochloric Acid SCHEMBL863452 | 0.65 | PIK3CD (0.45) | IRAK4PIK3CD | |
| SCHEMBL10938381 | 0.62 | IRAK4 (0.44) | IRAK4PDE1APDE1BPDE1C | |
| SCHEMBL863354 | 0.62 | PIK3CD (0.42) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | IRAK4 107/4885PIK3CD 14/4885PDE1A 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.